The Antiretroviral Speed Access Program Switch (ASAP-Switch) Study

This project builds on our experience with the ASAP Study (McGill University Health Centre research ethics board: MP-37-2020-4911). The goal of this study is to better understand the experience of migrant people with Human Immunodeficiency Virus (HIV) of having their treatment switched to Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF). In other words, the investigators want to evaluate how feasible and acceptable this switch is, and how participants will take B/F/TAF (fidelity) and remain on it. The investigators also want to know more about migrant people with HIV's experience of care; namely, how often they see their HIV specialist or other healthcare professionals, and their healthcare coverage (the type of insurance that they have).

NCT Number	NCT06375304
Lead Sponsor	McGill University Health Centre/Research Institute of the McGill University Health Centre
Conditions	HIV Infections
Enrollment	50 participants
Start Date	2024-05-01
Primary Completion	2026-06-01 (estimated)
Study Completion	2027-05-01 (estimated)
Updated on ClinicalTrials.gov	2024-04-19